PMID- 34719731
OWN - NLM
STAT- MEDLINE
DCOM- 20220518
LR  - 20220518
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Linking)
VI  - 239
IP  - 5
DP  - 2022 May
TI  - Acute effects of Delta(9)-tetrahydrocannabinol and cannabidiol on auditory mismatch 
      negativity.
PG  - 1409-1424
LID - 10.1007/s00213-021-05997-3 [doi]
AB  - RATIONALE: Mismatch negativity (MMN) is a candidate endophenotype for 
      schizophrenia subserved by N-methyl-D-aspartate receptor (NMDAR) function and 
      there is increasing evidence that prolonged cannabis use adversely affects MMN 
      generation. Few human studies have investigated the acute effects of cannabinoids 
      on brain-based biomarkers of NMDAR function and synaptic plasticity. OBJECTIVES: 
      The current study investigated the acute effects of Delta(9)-tetrahydrocannabinol 
      (THC) and cannabidiol (CBD) alone and in combination on the mismatch negativity 
      (MMN). METHODS: In a randomised, double-blind, crossover placebo-controlled 
      study, 18 frequent and 18 less-frequent cannabis users underwent 5 randomised 
      drug sessions administered via vaporiser: (1) placebo; (2) THC 8 mg; (3) CBD 
      400 mg; (4) THC 8 mg + CBD 4 mg [THC + CBD(low)]; (5) THC 12 mg + CBD 400 mg [THC 
      + CBD(high)]. Participants completed a multifeature MMN auditory oddball paradigm 
      with duration, frequency and intensity deviants (6% each). RESULTS: Relative to 
      placebo, both THC and CBD were observed to increase duration and intensity MMN 
      amplitude in less-frequent users, and THC also increased frequency MMN in this 
      group. The addition of low-dose CBD added to THC attenuated the effect of THC on 
      duration and intensity MMN amplitude in less-frequent users. The same pattern of 
      effects was observed following high-dose CBD added to THC on duration and 
      frequency MMN in frequent users. CONCLUSIONS: The pattern of effects following 
      CBD combined with THC on MMN may be subserved by different underlying 
      neurobiological interactions within the endocannabinoid system that vary as a 
      function of prior cannabis exposure. These results highlight the complex 
      interplay between the acute effects of exogenous cannabinoids and NMDAR function. 
      Further research is needed to determine how this process normalises after the 
      acute effects dissipate and following repeated acute exposure.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Greenwood, Lisa-Marie
AU  - Greenwood LM
AUID- ORCID: 0000-0002-0762-1921
AD  - Research School of Psychology, Australian National University, Canberra, ACT, 
      Australia. lisa-marie.greenwood@anu.edu.au.
AD  - The Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), 
      New Lambton Heights, NSW, Australia. lisa-marie.greenwood@anu.edu.au.
FAU - Broyd, Samantha J
AU  - Broyd SJ
AD  - School of Psychology and Illawarra Health and Medical Research Institute, 
      University of Wollongong, Wollongong, NSW, Australia.
FAU - van Hell, Hendrika H
AU  - van Hell HH
AD  - School of Psychology and Illawarra Health and Medical Research Institute, 
      University of Wollongong, Wollongong, NSW, Australia.
FAU - Todd, Juanita
AU  - Todd J
AD  - School of Psychology and Priority Research Centre for Brain and Mental Health, 
      University of Newcastle, Newcastle, NSW, Australia.
FAU - Jones, Alison
AU  - Jones A
AD  - Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, 
      NSW, Australia.
FAU - Murray, Robin M
AU  - Murray RM
AD  - Institute of Psychiatry, Psychology and Neuroscience, King's College London, 
      London, UK.
FAU - Croft, Rodney J
AU  - Croft RJ
AD  - School of Psychology and Illawarra Health and Medical Research Institute, 
      University of Wollongong, Wollongong, NSW, Australia.
FAU - Michie, Patricia T
AU  - Michie PT
AD  - School of Psychology and Priority Research Centre for Brain and Mental Health, 
      University of Newcastle, Newcastle, NSW, Australia.
FAU - Solowij, Nadia
AU  - Solowij N
AD  - The Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), 
      New Lambton Heights, NSW, Australia.
AD  - School of Psychology and Illawarra Health and Medical Research Institute, 
      University of Wollongong, Wollongong, NSW, Australia.
LA  - eng
GR  - NHMRC Project Grant 1007593/National Health and Medical Research Council of 
      Australia/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20211101
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Cannabinoids)
RN  - 0 (Hallucinogens)
RN  - 19GBJ60SN5 (Cannabidiol)
RN  - 7J8897W37S (Dronabinol)
SB  - IM
MH  - *Cannabidiol/pharmacology
MH  - *Cannabinoids
MH  - *Cannabis
MH  - Dronabinol/pharmacology
MH  - *Hallucinogens
MH  - Humans
OTO - NOTNLM
OT  - Brain electrophysiology
OT  - Cannabidiol (CBD)
OT  - Cannabis
OT  - Mismatch negativity (MMN)
OT  - Delta9-Tetrahydrocannabinol (THC)
EDAT- 2021/11/02 06:00
MHDA- 2022/05/19 06:00
CRDT- 2021/11/01 06:02
PHST- 2020/12/21 00:00 [received]
PHST- 2021/10/04 00:00 [accepted]
PHST- 2021/11/02 06:00 [pubmed]
PHST- 2022/05/19 06:00 [medline]
PHST- 2021/11/01 06:02 [entrez]
AID - 10.1007/s00213-021-05997-3 [pii]
AID - 10.1007/s00213-021-05997-3 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2022 May;239(5):1409-1424. doi: 
      10.1007/s00213-021-05997-3. Epub 2021 Nov 1.